Welcome to BlogNotions' Life Sciences Blog

The BlogNotions Life Sciences Blog delivers a diverse series of perspectives provided by thought leaders in the life sciences industries. Presented by NetLine, this forum delivers compelling updates on the latest technological advances, discussions of research and findings, best practices for advancing education, implications for the future of various life sciences fields, and much more. Here you can find helpful information, ask questions, and collaborate freely.

Eisai Announces FDA Approval of Fycompa (perampanel) Oral Suspension

In continuation of my update on Fycompa Eisai Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved Fycompa (perampanel) CIII Oral Suspension as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. The oral suspension […]

Continue Reading

Drug Patent Expirations for Sep 29, 2016

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. TRIZIVIR (abacavir sulfate; lamivudine; zidovudine) Viiv Hlthcare Patent number: 6,417,191 Expiration Date: Sep 28, 2016 TRIUMEQ (abacavir sulfate; dolutegravir sodium; lamivudine) Viiv Hlthcare Patent number: 6,417,191 […]

Continue Reading

Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion

In continuation of my update on vortioxetine Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) (collectively “Takeda”), and Lundbeck announced today that Brintellix(vortioxetine) will be marketed in the United States under the new name Trintellix(vortioxetine) starting in June of 2016. The vortioxetine product is a prescription medicine approved to treat Major Depressive […]

Continue Reading

New drug against nerve agents in sight

A model of how sarin and HI-6 are positioned in the protein acetylcholinesterase just before HI-6 removes sarin and restores the function of the protein. The model was developed by a combination of X-ray crystallography and quantum chemical calculations. Sarin in magenta, HI6 in green, oxygen in red, phosphorus in orange and nitrogen in blue.  […]

Continue Reading

Experimental Alzheimer’s drug reverses genetic changes thought to spur the disease

After treatment with riluzole, the brains of old rats showed more of a transporter molecule that removes excess glutamate, (green fluorescence, right) as compared to untreated rats (left). Aging takes its toll on the brain, and the cells of the hippocampus–a brain region with circuitry crucial to learning and memory–are particularly vulnerable to changes that […]

Continue Reading

Screening method uncovers drugs that may combat deadly antibiotic-resistant bacteria

In recent years, hospitals have reported dramatic increases in the number of cases of the highly contagious, difficult-to-treat, and often deadly antibiotic-resistant bacteria carbapenem-resistant Enterobacteriaceae (CRE). Now, investigators at Beth Israel Deaconess Medical Center (BIDMC) have developed a promising method of identifying new antimicrobials that target these organisms. The research is published in April issue […]

Continue Reading

New drug more effective in treating atrial fibrillation

Vernakalant, a new drug for treating recent-onset atrial fibrillation, has proved to be considerably more effective than Ibutilide, an established drug in this indication. It was able to normalize patients’ heart rhythm more rapidly and with fewer side-effects ocurring. This was revealed by a study conducted at the Department of Emergency Medicine at Medical University […]

Continue Reading

Drug Patent Expirations for Sep 22, 2016

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. JENTADUETO XR (linagliptin; metformin hydrochloride) Boehringer Ingelheim Patent number: 6,340,475 Expiration Date: Sep 19, 2016 JENTADUETO XR (linagliptin; metformin hydrochloride) Boehringer Ingelheim Patent number: 6,635,280 Expiration […]

Continue Reading

Expand prescribing of buprenorphine for opioid abuse? Experts weigh pros and cons….

In continuation of my update on Buprenorphine Buprenorphine is a critical part of treatment for the growing epidemic of opioid abuse–but also carries the potential for misuse and diversion. The debate over whether ‘to expand or not to expand’ prescribing of buprenorphine for opioid abuse is discussed in an expert review in the Journal of Psychiatric Practice, published […]

Continue Reading